These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 4154991)

  • 1. Long-lasting anti-tremor induced by 2-Br-alpha-ergocryptine in monkeys.
    Miyamoto T; Battista A; Goldstein M; Fuxe K
    J Pharm Pharmacol; 1974 Jun; 26(6):452-4. PubMed ID: 4154991
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trial of 2-Br- -ergocryptine (CB154) in advanced breast cancer.
    Eur J Cancer (1965); 1972 Apr; 8(2):155-6. PubMed ID: 4561333
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of 2-Br-alpha-Ergocryptine, L-dopa and cyclic imides on serum prolactin in postmenopausal women.
    Rozencweig M; Heuson JC; Bila S; L'Hermite M; Robyn C
    Eur J Cancer (1965); 1973 Sep; 9(9):657-64. PubMed ID: 4803232
    [No Abstract]   [Full Text] [Related]  

  • 4. [Postpartal lactation inhibition by 2-Br-alpha-ergocryptine: I. A comparative study with 2-Br-alpha-ergocryptine in different dosages and placebo (author's transl)].
    Varga L; Radielovic P
    Geburtshilfe Frauenheilkd; 1974 Oct; 34(10):882-4. PubMed ID: 4613600
    [No Abstract]   [Full Text] [Related]  

  • 5. [Advances in the treatment of the galactorrhoea-amenorrhoea-syndrome: Induction of ovulation and inhibition of lactation with 2-Br-alpha-ergo-cryptine (author's transl)].
    Jaszmann L; Sternthal V
    Geburtshilfe Frauenheilkd; 1974 Jan; 34(1):59-64. PubMed ID: 4816922
    [No Abstract]   [Full Text] [Related]  

  • 6. Ergocornine and 2-Br-alpha-ergocryptine. Evidence for prolonged dopamine receptor stimulation.
    Fuxe K; Corrodi H; Hökfelt T; Lidbrink P; Ungerstedt U
    Med Biol; 1974 Apr; 52(2):121-32. PubMed ID: 4837435
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine.
    Thorner MO; McNeilly AS; Hagan C; Besser GM
    Br Med J; 1974 May; 2(5916):419-22. PubMed ID: 4600593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proceedings: Comparative animal experiments on the effectivity of various endocrine therapeutic methods in hormone dependent breast carcinoma].
    Schulz KD; Ahrens J
    Arch Gynakol; 1973 Sep; 214(1):296-7. PubMed ID: 4801462
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopaminephilic properties of ergot alkaloids.
    Goldstein M; Lew JY; Nakamura S; Battista AF; Lieberman A; Fuxe K
    Fed Proc; 1978 Jun; 37(8):2202-6. PubMed ID: 26607
    [No Abstract]   [Full Text] [Related]  

  • 10. Successufl ovulation and pregnancy achieved by cb-154 (2-br-alpha-ergocryptine) in a woman with Chiari-Frommel syndrome.
    Seki K; Seki M
    J Clin Endocrinol Metab; 1974 Mar; 38(3):598-9. PubMed ID: 4815181
    [No Abstract]   [Full Text] [Related]  

  • 11. [Postpartal lactation inhibition by 2-Br-alpha-ergocryptine: II. A comparative study with 2-Br-alpha-ergocryptine and methallenoestrol (author's transl)].
    Varga L; Radielovic P
    Geburtshilfe Frauenheilkd; 1974 Oct; 34(10):885-7. PubMed ID: 4442688
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of galactorrhea-amenorrhea syndrome with Br-ergocryptine (CB 154): restoration of ovulatory function and fertility.
    Varga L; Wenner R; Del Pozo E
    Am J Obstet Gynecol; 1973 Sep; 117(1):75-9. PubMed ID: 4722381
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-tremor activity of talipexole produced by selective dopamine D2 receptor stimulation in cynomolgus monkeys with unilateral lesions in the ventromedial tegmentum.
    Kohno Y; Fukuzaki K; Kitahara K; Koja T
    Eur J Pharmacol; 1997 Jan; 319(2-3):197-205. PubMed ID: 9042591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of non-puerperal galactorrhoea with an ergot alkaloid.
    Lutterbeck PM; Pryor JS; Varga L; Wenner R
    Br Med J; 1971 Jul; 3(5768):228-9. PubMed ID: 5105219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.
    Goldstein M; Lieberman A; Battista AF; Lew JY; Hata F
    Pharmacology; 1978; 16 Suppl 1():143-9. PubMed ID: 25445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromocriptine treatment of acromegaly.
    Thorner MO; Chait A; Aitken M; Benker G; Bloom SR; Mortimer CH; Sanders P; Mason AS; Besser GM
    Br Med J; 1975 Feb; 1(5953):299-303. PubMed ID: 1111790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable reduction of plasma growth hormone (hGH) levels during chronic administration of 2-Br-alpha-ergocryptine (CB-154) in acromegalic patients.
    Chiodini PG; Liuzzi A; Botalla L; Oppizzi G; Müller EE; Silvestrini F
    J Clin Endocrinol Metab; 1975 Apr; 40(4):705-8. PubMed ID: 1127079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tremor and involuntary movements in monkeys: effect of L-dopa and of a dopamine receptor stimulating agent.
    Goldstein M; Battista AF; Ohmoto T; Anagnoste B; Fuxe K
    Science; 1973 Feb; 179(4075):816-7. PubMed ID: 4630708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromocriptine in Parkinsonism.
    Calne DB; Teychenne PF; Claveria LE; Eastman R; Greenacre JK; Petrie A
    Br Med J; 1974 Nov; 4(5942):442-4. PubMed ID: 4425916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced relief of experimental tremor in monkeys.
    Goldstein M; Battista AF; Nakatani S; Anagnoste B
    Neurology; 1970 Nov; 20(11):89-95. PubMed ID: 4991252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.